An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT03279263
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 400 participants
- Sponsor
- Melior Pharmaceuticals
- Registry
-
NCT03279263
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT03279263. Randomized; triple masking; primary purpose treatment. Start 2017-09-01 (actual); primary completion 2019-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- MLR-1023
- Intervention (Other)
- Placebo
- Lead sponsor
- Melior Pharmaceuticals
- Collaborator
- Bukwang Pharmaceutical, Co., Ltd.
Record details
- Record id
cardio:ct-nct03279263- Content hash
cdf49624ce280ac9a457566e8d32329a14c950cbc00303a1479b68d84e02781e